PharmaLytica 2024 to draw 200+ exhibitors
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Around 7% of the Indian population suffers from IBS
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Submission based on results from pivotal phase III trial showing all primary endpoints met
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The demand in Africa for COVID-19 vaccines has declined
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
Subscribe To Our Newsletter & Stay Updated